Article Information
History
- July 30, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Mahmoud Zureik, M.D., Ph.D.1,4,†,
- Bérangère Baricault1,
- Clémentine Vabre, Pharm.D1,
- Laura Semenzato1,
- Jérôme Drouin1,
- François Cuenot, Ph.D.1,
- Laetitia Penso1,
- Philippe Herlemont1,
- Emilie Sbidian, M.D., Ph.D1,2,
- Alain Weill, M.D.1,
- Mathieu Molimard, M.D., Ph.D3,
- Rosermary Dray-Spira, M.D., Ph.D1 and
- Jérémie Botton, Ph.D.*,1
- 1EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products and the French National Health Insurance
- 2University Paris-Est Créteil, Research Unit Epidemiology in dermatology and evaluation of therapeutics
- 3Service of medical pharmacology, university of Bordeaux, Inserm, UMR 1219, Bordeaux population health research center
- 4University Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Anti-infective evasion and pharmacoepidemiology, CESP, 78180, Montigny le Bretonneux, France
- ↵†Corresponding Author: Pr. Mahmoud Zureik, Director of EPI-PHARE, Mahmoud.zureik{at}ansm.sante.fr
Posted July 30, 2020.
Nicotine-replacement therapy, as a surrogate of smoking, and the risk of hospitalization with Covid-19 and all-cause mortality: a nationwide, observational cohort study in France
